AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iyer, R. P.
Right arrow Articles by Morrey, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iyer, R. P.
Right arrow Articles by Morrey, J. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2004, p. 2318-2320, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2318-2320.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model

Radhakrishnan P. Iyer,1,{dagger} Arlene Roland,2 Yi Jin,1 Samir Mounir,1 Brent Korba,2 Justin G. Julander,3 and John D. Morrey3*

Origenix Technologies, Inc., St. Laurent, Quebec, Canada,1 Division of Molecular Virology and Immunology, Georgetown University, Rockville, Maryland,2 Institute for Antiviral Research, Animal, Dairy, and Veterinary Sciences Department, Utah State University, Logan, Utah3

Received 31 March 2003/ Returned for modification 30 May 2003/ Accepted 25 November 2003

ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P <= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.

* Corresponding author. Mailing address: Biotechnology Center, Rm. 305, 4700 Old Main Hill, Utah State University, Logan, UT 84322-4700. Phone (435) 797-2622. Fax (435) 797-2766. E-mail: jmorrey{at}cc.usu.edu.

{dagger} Present address: Spring Bank Technologies, Inc., Worcester, Mass.

Antimicrobial Agents and Chemotherapy, June 2004, p. 2318-2320, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2318-2320.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.